ReviewProstate international2024
Risks and side effects in the medical management of benign prostatic hyperplasia.
Review in Prostate international, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- SHProInvestigative and clinical urology · 2025Trial
- Dissemination of misleading and biased information about benign prostate hyperplasia on YouTube in the Republic of Korea.Prostate international · 2026Article
- Myricetin alleviates testosterone-induced benign prostatic hyperplasia by attenuating inflammation, oxidative stress, apoptosis and androgen signaling.Scientific reports · 2026Article
- [Pharmacotherapy of benign prostatic syndrome : Medications, innovations and future prospects].Urologie (Heidelberg, Germany) · 2026Review
- Efficacy and Safety of Mirabegron and Tamsulosin Combination Therapy Compared to Tamsulosin Monotherapy for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: Results of a Multicenter, Randomized, Double-Blind, Phase III Clinical Trial.The world journal of men's health · 2026Article
- The efficacy of tamsulosin 0.4 mg when tamsulosin 0.2 mg is insufficient for benign prostatic hyperplasia in Korean patients.Investigative and clinical urology · 2026Article
- The "swipe" technique for prostatic urethral lift: a comparative analysis of 200 patients in a prospective cohort.Prostate international · 2026Article
- Real-world comparison of RezūmWorld journal of urology · 2026Article
- Evaluation of safety reporting in interventional trials of benign prostatic hyperplasia: a registry-publication comparison study.BMC urology · 2026Article
- Letter to the editor: Aquablation versus HoLEP: Propensity score matching analysis of functional outcomes and ejaculation preservation.Investigative and clinical urology · 2026Article
- Risk of BPH-LUTS according to the PM₁₀ exposure: A longitudinal nationwide cohort-based study.Investigative and clinical urology · 2026Article
- Transurethral water vapor therapy (Rezūm) for acute urinary retention with obstructive uropathy: a prospective cohort study with one-year follow-up.Prostate international · 2025Article
- Liver fibrosis is associated with men's health care symptoms, especially erectile dysfunction and lower urinary tract symptoms.Investigative and clinical urology · 2025Article
- Airborne chloride exposure and benign prostatic hyperplasia risk.BMC research notes · 2025Article
- Identification of genes related to the effects of bicalutamide and zoladex on benign prostatic hyperplasia.Scientific reports · 2025Article
- Aquablation versus HoLEP: Propensity score matching analysis of functional outcomes and ejaculation preservation.Investigative and clinical urology · 2025Article
- Association between truncal muscle mass index measured by bioelectrical impedance analysis and overactive bladder symptoms in men: A retrospective cross-sectional analysis.Investigative and clinical urology · 2025Article
- A randomized, active-controlled, multicenter, phase 3 clinical trial to evaluate the efficacy and safety of GV1001 in patients with benign prostatic hyperplasia.Prostate international · 2025Article
- Article
- Sex hormones, blood metabolites and proteins mediating the causal associations between gut microbiota and prostatic diseases: evidences from Mendelian randomization study.Prostate international · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Benign prostatic hyperplasia affects up to 80% of men in their lifetime. It causes bladder outflow obstruction, leading to lower urinary tract symptoms, which can have a large impact on quality of life. Lifestyle modifications and pharmacotherapy are often offered as first-line treatments for patients. These include alpha blockers, 5-alpha-reductase inhibitors, phosphodiesterase-5 inhibitors, anticholinergics, B3-agonists, and desmopressin. While often well tolerated, these pharmacotherapies do have significant side effects, which both clinicians and patients should understand and discuss in order to make an informed treatment decision among alternatives. The purpose of this review is to provide a current overview of the risks and side effects of commonly used medications in benign prostatic hyperplasia management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.